UBS Group AG Buys 31,590 Shares of Dyne Therapeutics, Inc. $DYN

UBS Group AG increased its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 9.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 380,978 shares of the company’s stock after acquiring an additional 31,590 shares during the quarter. UBS Group AG owned about 0.27% of Dyne Therapeutics worth $7,452,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in shares of Dyne Therapeutics by 14.9% in the 4th quarter. Vanguard Group Inc. now owns 11,215,565 shares of the company’s stock valued at $219,376,000 after purchasing an additional 1,455,151 shares during the period. TCG Crossover Management LLC raised its holdings in Dyne Therapeutics by 22.5% during the 3rd quarter. TCG Crossover Management LLC now owns 4,615,144 shares of the company’s stock worth $58,382,000 after buying an additional 848,484 shares during the period. JPMorgan Chase & Co. lifted its stake in Dyne Therapeutics by 9.0% in the third quarter. JPMorgan Chase & Co. now owns 3,365,245 shares of the company’s stock valued at $42,570,000 after buying an additional 278,466 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new position in Dyne Therapeutics in the second quarter valued at approximately $30,378,000. Finally, Armistice Capital LLC boosted its holdings in shares of Dyne Therapeutics by 19.7% in the third quarter. Armistice Capital LLC now owns 3,064,000 shares of the company’s stock valued at $38,760,000 after buying an additional 504,000 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, Director Jason P. Rhodes sold 287,956 shares of the company’s stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $19.68, for a total value of $5,666,974.08. Following the transaction, the director directly owned 11,663 shares of the company’s stock, valued at $229,527.84. This represents a 96.11% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,559,462 shares of company stock valued at $29,814,746 over the last 90 days. 14.14% of the stock is currently owned by corporate insiders.

Dyne Therapeutics Stock Performance

Shares of DYN stock opened at $16.54 on Tuesday. The stock has a market cap of $2.73 billion, a P/E ratio of -5.14 and a beta of 1.08. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92. The company has a fifty day moving average price of $18.36 and a two-hundred day moving average price of $18.53. Dyne Therapeutics, Inc. has a one year low of $8.06 and a one year high of $25.00.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.04. During the same period last year, the firm earned ($1.05) earnings per share. As a group, equities analysts predict that Dyne Therapeutics, Inc. will post -2.99 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Jefferies Financial Group reiterated a “buy” rating on shares of Dyne Therapeutics in a report on Monday, March 9th. Wall Street Zen raised Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Monday, April 20th. Sanford C. Bernstein lifted their target price on Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. Finally, HC Wainwright cut their target price on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, March 3rd. Three analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $35.00.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.